Cipla has announced its Q1 financial results, with a consolidated net profit of ₹1291.61 crore, marking a 10% increase from the previous year. The company’s revenue from operations also saw growth, standing at ₹6,957.47 crore. Domestic sales contributed significantly, with One India sales reaching ₹3070 crore, a 6% year-on-year increase. Cipla’s success in launching new products like Voltido Trio in the respiratory portfolio has been highlighted.
In the US market, despite facing challenges from increased competition in generic products like Revlimid, Cipla’s sales stood at $229 million, contributing around 28% to the company’s overall sales. The company’s respiratory product Albuterol and hormonal treatment drug Lanreotide have shown strong market performance. Additionally, Cipla has expanded its oncology portfolio with the launch of Nano Paclitaxel and Nilotinib, along with an upcoming biosimilar product launch in the US. Overall, Cipla’s Q1 results reflect a positive growth trajectory amidst competitive market conditions.
Read more from livemint.com